natgillin/translations-raw huggingface dataset:
Other aspects of the invention are methods for the immunological determination of an antibody against the amyloid B peptide in a sample using an immunoassay and for the immunological determination of an anti-idiotype antibody against an antibody against the amyloid B peptide in a sample using an immunoassay. In an embodiment of the method for the immunological determination of an antibody against the amyloid B peptide in a sample the immunoassay comprises a capture antibody, a tracer antibody and a detection antibody, wherein the capture antibody is a biotinylated anti-idiotype antibody against an antibody against the amyloid B peptide conjugated to a solid phase via streptavidin, the tracer antibody is an anti-idiotype antibody against an antibody against the amyloid B peptide conjugated to digoxygenin as detectable label, and the detection antibody is an antibody against digoxygenin conjugated to horseradish peroxidase. 
Postupak za imunološko određivanje protutijela za amiloid-B-peptid, naznačen time, da se provodi u uzorku uporabom imunološke analize koja se primjenjuje na protutijelu koje se dobiva iz stanične linije DSM ACC2939, pri čemu imunološka analiza obuhvaća protutijelo za hvatanje, protutijelo za traganje i protutijelo za otkrivanje, dok spomenuto protutijelo za hvatanje je biotinilirano anti-idiotipično protutijelo koje je protiv protutijela za amiloid-B-peptid, dobiveno iz stanične linije DSM ACC2939, i konjugirano preko streptavidina na krutu fazu, gdje protutijelo za traganje je anti-idiotipično protutijelo koje je protiv protutijela za amiloid-f3- peptid, dobiveno iz stanične linije DSM ACC2939, 1 konjugirano na digoksigenin koji služi kao oznaka koja se može otkrivati, te spomenuto protutijelo za otkrivanje je protutijelo protiv digoksigenina, konjugirano na peroksidazu.
3.06 19 The method according to any one of claims 1 to 5, characterised by an X-ray powder diffraction pattern, made using CuKa1 radiation, which comprises peaks at degrees 2Θ (±0.1 degrees 2Θ) as shown in Figure 1. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time, da ima karakterističan uzorak difrakcije praha X-zraka, koji se dobiva uporabom CuKa1-radijacije, i koji obuhvaća vršne vrijednosti u stupnjevima 2θ (± 0,1 stupanj 2θ), kako je prikazano na Slici 1.
the deletion between the first and second CRISPR RNA recognition sequences in the first homologous chromosome, and an insertion of the nucleic acid insert between the 5′ and 3′ target sequences in the first homologous chromosome, wherein the nucleic acid insert sequence is homologous or orthologous to the deleted sequence. 
delecija između prve i druge CRISPR RNA sekvence prepoznavanja u prvom homologu kromosom, a umetanje inserta nukleinske kiseline između 5 'i 3' ciljnih sekvencija u prvom homologni kromosom, pri čemu je sekvenca umetanja nukleinske kiseline homologna ili ortologna s izbrisanim sekvenca;
Method for monitoring the quality of a transmitted digital video signal with the steps of: 
Postupak praćenja kvalitete odaslanog digitalnog video signala koracima:
In a further embodiment in said step d) is said cultivating in the presence of said eukaryotic selection agents in a volume of less than 500 liter and said cultivating is in the absence of said eukaryotic selection agents in a volume of 500 liter or more, whereby said recovering said secreted heterologous immunoglobulin is from the cultivation medium without said eukaryotic selection agents. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da u spomenutom koraku d) navedeno kultiviranje u prisutnosti spomenutih eukariotskih selekcijskih agenasa ima volumen manji od 500 litara te time, da spomenuto kultiviranje u odsutnosti spomenutih eukariotskih selekcijskih agenasa ima volumen od 500 litara ili više te time, da se spomenuto obnavljanje navedenog izlučenog heterolognog imunoglobulina, vrši iz medija za uzgoj bez spomenutih eukariotskih selekcijskih agenasa.
The extended release dosage form of any one of claims 1 to 28, which is in the form of a tablet formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C or at least about 62 °C for a time period of at least about 1 minute, preferably at least about 5 minutes or at least about 15 minutes. 
Oblik doziranja sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 12, naznačen time da je u obliku tablete oblikovane pomoću direktnog prešanja pripravka, te koja je stvrdnuta barem podvrgavanjem navedene tablete temperaturi od najmanje oko 60°C ili najmanje oko 62°C u vremenskom periodu od najmanje oko 1 minute, poželjno najmanje oko 5 minuta ili najmanje oko 15 minuta.
is selected from the structures: 
R* izabran iz struktura:
The cell according to claim 34, comprising at least one nucleic acid encoding a protein molecule or at least one part thereof, and at least one nucleic acid comprising at least one nucleic acid sequence encoding at least one polypeptide having an amino acid sequence selected from the group consisting of SEQ ID No: 1 to 9. 
Upotreba imortalizirane stanice iz ljudske krvi u skladu s bilo kojim od patentnih zahtjeva 39 do 42, naznačena time što imortalizirana stanica iz ljudske krvi sadrži najmanje jednu nukleinsku kiselinu koja kodira molekulu proteina ili najmanje jedan njezin dio u ekspresijskom vektoru prikladnom za proizvodnju navedenog proteina ili navedenog njegovog dijela.
System for treating water at low cost, according to claim 1, wherein the receiving means is covered with a material comprising membranes, geo-membranes, geotextile membranes, plastic liners, concrete, or coated concrete, or a combination thereof. 
Uređaj iz patentnog zahtjeva 1, pri čemu je sredstvo prihvaćanja prekriveno materijalom koji obuhvaća membrane, geomembrane, geotekstilne membrane, plastične podloške, beton, obloženi beton, ili njihove kombinacije.
The use of claim 20, wherein the complex wound is a venous ulcer, a decubitus ulcer or a burn. 
Čestice za uporabu prema patentnom zahtjevu 14, pri čemu je složena rana ulkus dijabetičkog stopala, venski ulkus, dekubitalni ulkus ili opeklina.
further comprises an effector moiety that is a detectable moiety or a functional moiety, wherein said detectable moiety is optionally a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material and said functional moiety optionally is streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, or a radioactive material. 
(ii) dodatno sadrži efektorski ostatak koji je detektibilni ostatak ili funkcionalni ostatak, gdje navedeni detektibilni ostatak može biti fluorescentno bojilo, enzim, supstrat, bioluminescentni materijal, radioaktivni materijal, ili kemiluminescentni materijal, navedeni funkcionalni ostatak može biti streptavidin, avidin, biotin, citotoksin, citotoksično sredstvo, ili radioaktivni materijal.
The amount of the starch component, excluding any starch which may be present in the flour, may comprise about 20-35% more preferably about 29% most preferably about 28.8% by weight of the dry ingredients. 
Postupak za proizvodnju prehrambenog proizvoda prema patentnom zahtjevu 1, naznačen time što je količina modificiranog škroba u kompoziciji smjese za pohanje 15 do 35% prema suhoj težini.
providing a hydrophobic solvent; 
dobivanje hidrofobnog otapala;
95°C, and at the outlet of the flash cooler less than 60 to 30°C, e.g. 
95°C, te na izlazu iz brzog hladila manje od 60 do 30 °C, npr.
A strong cation exchanger contains a strong acid (such as a sulfopropyl group) that remains charged from pH 1-14; whereas a weak cation exchanger contains a weak acid (such as a carboxymethyl group), which gradually loses its charge as the pH decreases below 4 or 5. 
Jaki kationski izmjenjivač sadrži jaku kiselinu (poput sulfopropilne skupine) koja ostaje nabijena kod pH od 1 do 14; dok slabi kationski izmjenjivač sadrži slabu kiselinu (poput karboksimetilnu skupinu) koja postupno ispušta svoj naboj sa smanjenjem pH ispod 4 ili 5.
The protected amine can be prepared from the properly substituted (2-mercapto-benzyl)-methyl-carbamic acid ester and the properly substituted 5-halo indole or 5-pseudohalo indole, where “halo” is either bromo or iodo and “pseudohalo” is e.g. triflate or nonaflate, as described in method 9. 
Zaštićeni amin može se pripremiti iz pravilno supstituiranih (2-merkapto-benzil)-metil-karbamski kiselog estera 1 pravilno supstituiranog 5-halo indola ili 5-pseudohalo indola gdje je "halo" ili brom ili jod, a "pseudohalo" je triflat ili nonaflat kako je to opisano u metodi 9.
Device according to claim 2, characterized in that the mobile element (29) is driven in displacement according to a linear movement. 
Uređaj sukladno zahtjevima 1 ili 2, naznačen time, što je mobilni element (29) pogonjen u zamahu da vrši linearno kretanje.
The method of claim 1, wherein if the size of the transform unit is larger than 8×8, the diagonal scan is applied for all intra prediction modes. 
Postupak prema Zahtjevu 1, gdje ukoliko je veličina transformacijske jedinice veća od 8x8, za sve intrapredikcijske režime primjenjuje se dijagonalno skeniranje.
A liquid-phase process for preparing Degarelix having the formula Ac-AA1-AA10-NH2: or a pharmaceutically acceptable salt or solvate thereof; 
Postupak u tekućoj fazi za pripravu Degareliksa formule Ac-AA1-AA10-NH2:
Adhesive composition according to any one of claims 1 or 2, wherein said cation of the alkyl ether sulphate salt is a cation of organic origin, preferably having formula RR1R2NH+, wherein R, R1 and R2, independently from each other, are selected from hydrogen, ethyl, propyl, isopropyl, butyl, isobutyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxyisopropyl provided that at least one of the groups R, R1 and R2 is different from a hydrogen atom and, more preferably, one of the substituents R, R1 and R2 is equal to hydroxyisopropyl and the remaining two are a hydrogen atom. 
Adhezivna kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 ili 2, pri čemu navedeni kation soli alkil eter sulfata je kation organskog porekla, poželjno koji ima formulu RR,R>NH", pri čemu R, R, i Rx, nezavisno jedan od drugog, su odabrani od vodika, etila, propila, izopropila, butila, izobutila, hidroksietila, hidroksipropila, hidroksibutila, hidroksiizopropila pod uvjetom da najmanje jedna od grupa R, R, i R, se razlikuje od atoma vodika i, još poželjnije, jedan od supstituenata R, R, i R2 je jednak hidroksiizopropilu a preostala dva su atom vodika.
The spreading-material container according to claim 12, wherein the liquid tank has arranged therein an expandable apparatus which is made at least partly of an elastic material, so that it can expand and contract. 
Spremnik tekućine u skladu s patentnim zahtjevom 12, naznačen time što se u spremniku tekućine (10) nalazi proširljivi uređaj (30), koji se po mogućnosti u najmanju ruku djelomično sastoji od elastičnog materijala, tako da se može proširiti poput balona.
pressure testing the first volume while the second volume is at the initial pressure and separated from the first volume, 
tlačno ispitivanje prvog volumena (V1) dok je drugi volumen (V2) na početnom tlaku i odvojen od prvog volumena (V1),
Use as claimed in claim 8, for the manufacture of a medicament for the treatment or prevention of rheumatoid arthritis. 
Spoj za uporabu prema zahtjevu 4 za liječenje ili prevenciju reumatoidnog artritisa.
A derivative according to any one of claims 1-16 for use in a method of treatment and/or prevention of any one of all forms of diabetes and related diseases, such as obesity, eating disorders, cardiovascular diseases, diabetic complications; and/or for improving lipid parameters, improving B-cell function; and/or for delaying or preventing diabetic disease progression; and/or for of treatment and/or prevention of hepatic steatosis and non-alcoholic fatty liver disease (NAFLD). 
Derivat u skladu s bilo kojim od patentnih zahtjeva 1-16, naznačen time što je namijenjen upotrebi u postupku liječenja i/ili sprječavanja bilo kojih od svih oblika dijabetesa i srodnih bolesti, poput pretilosti, poremećaja uzimanja hrane, kardiovaskularnih bolesti, komplikacija dijabetesa; i/ili poboljšavanja parametara lipida, poboljšavanja funkcije B-stanica; i/ili odgađanju ili sprječavanju napredovanja dijabetične bolesti; i/ili liječenju i/ili sprječavanju steatoze jetre i nealkoholne bolesti masne jetre (NAFLD).
A use according to claim 12, wherein Enteroviral particles are of an Enterovirus selected from the group consisting of polioviruses, Coxsackie A viruses, Coxsackie B viruses, Echoviruses, Rhinoviruses and Enteroviruses 68, 69, 70, 71 and 73 
Upotreba prema patentnom zahtjevu 12, naznačena time što su enterovirusne čestice iz roda Enterovirus odabrano iz grupe koja se sastoji od poliovirusa, Coxsackie A virusa, Coxsackie B virusa, ehovirusa, rinovirusa i enterovirusa 68, 69, 70, 71 173
The compositions of the present invention may contain a wide range of additional, optional components. 
Pripravci iz ovog izuma mogu sadržavati širok opseg dodatnih, opcionalnih sastojaka.
A method for treating depression, anxiety or bipolar disorder in a mammal, comprising administering an effective amount of the pharmaceutical composition of claim 2 to the mammal. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da je to sredstvo koje se upotrebljava za profilaksu ili liječenje depresije, anksioznosti ili bipolarnog poremećaja.
The functional disorder recovery-enhancing agent and/or the functional disorder alleviation-enhancing agent for a patient with nerve injury to undergo rehabilitation according to claim 6, wherein the alkyl ether derivative is 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol. 
Derivat alkil etera predstavljen općom formulom [1] ili njegova sol za uporabu u skladu s patentnim zahtjevom 6, naznačen time, da je derivat alkil etera 1-(3-(2-(l-benzotiofen-5-il) etoksi)propil)azetidin-3-ol.
or 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine-1-oxide or a pharmaceutically acceptable salt thereof. 
ili jest 4-(3-metansulfonil-fenil)-1-propil-piperidin-1-oksid ili njegova farmaceutski prihvatljiva sol.
Valve (10) according to claim 7, wherein said plane is inclined of about 45° with respect to said axis (A). 
Ventil (10) u skladu s patentnim zahtjevom 7, pri čemu je navedena ravnina nakošena oko 45% u odnosu na navedenu os (A).
This portion is extracted with DCM (2 x 3 ml) and the organic extracts are combined and concentrated in vacuo to yield the titled compound as a white solid. 
Taj dio se ekstrahira s DCM-om (2 x 3 ml) i organski ekstrakti se sjedine i koncentriraju u vakuumu, čime se dobije naslovni spoj kao bijela kruta tvar.
The method of claim 12, wherein the plant cell is a maize cell. 
Postupak prema zahtjevu 10, naznačen time, da se kod biljne stanice radi o stanici kukuruza.
The method of paragraph 9, wherein at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% of said transposome complexes in solution comprise a second tag comprising a second tag domain. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 7-9, naznačen time što najmanje 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % navedenih transposomskih kompleksa u otopini sadrži drugi biljeg, koji sadrži drugu bilježnu domenu.
The system of claim 1 wherein direct current for spinal stimulation ranges from about 2 ma to about 5 mA for treatment of muscle tone in humans. 
Sustav sukladno zahtjevu 1 pri čemu je navedena istosmjerna struja za spinalnu stimulaciju opsega od otprilke 2 ma do otprilike SmA za terapiju mišićnog tonusa kod ljudi.
is optionally substituted phenyl; 
R> je izborno supstituirani fenil;
drying the precipitate at a temperature ranging from room temperature to 40°C under a pressure ranging from ambient pressure to 0.001 Torr, for a duration of time ranging from 10 minutes to 1 day, and optionally in the presence of dehydrating agents. 
– sušenja taloga na temperaturi u rasponu od sobne temperature do 40 °C pod tlakom u rasponu od okolišnog tlaka do 0,001 Torr (133,32 Pa), u trajanju u rasponu od 10 minuta do 1 dana.
Male and female CD-1 mice 9-12 weeks of age are dosed with a compound of formula I rug by oral gavage. A range of doses is selected in an effort to determine a maximum tolerated dose and dose limiting toxicity. 
Mužjacima i ženkama CD-1 miševim stari 9-12 tjedana oralno je doziran spoj formule I. Raspon doza odabran je tako da se odredi maksimalna podnošljiva doza i toksičnost koja ograničuje dozu.
These and other aspects of the invention disclosed herein will be set forth in greater detail as the patent disclosure proceeds. 
Ovi navedeni i ostali aspekti izuma sadržani u ovom tekstu, biti će detaljnije opisani tijekom opisa patentne prijave.
A method according to claim 1 or 2, wherein said gene B is part of the genome of the cell. A method according to any one of claims 1 to 3, wherein the cell is co-transformed with at least two different genes A1 and A2 and optionally with at least two different genes B1 and B2. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu se stanice nazivaju kotransformiranima s najmanje dvije različite varijante gena A za rekombinaciju, koji su geni A1 1 A2, i neobavezno s najmanje dvije različite varijante gena B za rekombinaciju, koji su geni B1 i B2.
a compound having the formula 
Spoj naznačen time da ima formulu
The method according to claim 4, wherein the cardiovascular disease is ischemic heart disease. 
Spoj za primjenu prema patentnom zahtjevu 8, naznačen time, da kardiovaskularna bolest jest ishemijska bolest srca.
-G-Ry where G is a direct bond, C(=O) or C(=O)O and Ry is selected from C1-C7 aliphatic substituted by one or more halogens and/or one or two functional groups selected from hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, acyl having 4 in-chain atoms, acyloxy having 4 in-chain atoms, carboxy, sulfo, sulfamoyl, carbamoyl, cyano, azo, or nitro, which hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, carboxy, sulfo, sulfamoyl, carbamoyl and cyano groups are in turn optionally substituted on at least one heteroatom by one or, where possible, more C1-C7 aliphatic groups, 
ravni ili razgranati alkil koji ima 1, 2, 3 ili 4 atoma ugljika, ravni ili razgranati alkil koji ima 1, 2, 3 ili 4 atoma ugljika supstituiranih jednim ili više halogena i/ili jednom ili dvije funkcionalnih skupina odabranima od sljedećih: hidroksi, amino, amidino, guanidino, hidroksiguanidino, formamidino, izotioureido, ureido, merkapto, niži acil, niži aciloksi, karboksi, sulfo, sulfamoil, karbamoil, cijano, azo ili nitro, dok hidroksi, amino, amidino, guanidino, hidroksiguanidino, formamidino, izotioureido, ureido, merkapto, karboksi, sulfo, sulfamoil, karbamoil i cijano skupine su u obrtaju supstituirane na barem jednom heteroatomu s jednom ili, gdje je to moguće, više ravnih ili razgranatih alkilnih skupina koje imaju 1, 2, 3 ili 4 atoma ugljika,
The method of any of claims 12 to 14 wherein the larger particles are circulating endothelial cells and the smaller particles are blood cells. 
Postupak prema bilo kom od patentnih zahtjeva 12 do 14, pri čemu veće čestice jesu cirkulirajuće endotelne stanice HR P20160395 T1 a manje čestice jesu stanice krvi.
The fractions containing the product were combined and concentrated to afford intermediate 3 as a dark paste (0.8639 g, 28.6%). 
Frakcije koje sadrže proizvod su spojene i koncentrirane da bi se dobio intermedijer 3 kao tamna pasta (0.8639 g, 28.6%).
wherein the pawl-and-teeth mechanism is configured such that reciprocal movement of the counter driver within the bore of the second ring member causes rotational movement of the second ring member. A dispenser according to claim 45, wherein the body comprises a counter driver guide configured to guide the counter driver in the body so as to prevent rotation of the counter driver in the longitudinal axis. 
Dispenzer u skladu sa patentnim zahtjevom 28, gdje tijelo (1) sadrži vođicu (230, 220) pokretača brojača koja je konfigurirana da navodi pokretača (206) brojača u tijelo tako da se spriječi rotacija pokretača brojača u longitudinalnoj osi.
Bioavailabiity is assessed by calculating the quotient between the area under blood/plasma concentration (AUC) curve following (i) intraduodenal (i.d.) 
Bioprihvatljivost je analizirana izračunavanjem koeficijenta površine ispod krivulje koncentracije krvi/plazme (AUC) između (1) intraduodcnalnu (i.d.)
represents the substituted imidazol-5-yl of Formula (II) as defined in claim 1, wherein: 
R3 predstavlja supstituirani imidazol-5-il formule (II) definiran u zahtjevu 1, naznačen time, da:
substituted and unsubstituted alkyl, -COR2a, and -NR2aCOR2b, wherein R2a, and R2b are independently selected from the group consisting of 
(9) -NRxCORx, gdje R2, i Ry su neovisno odabrani iz skupine koja sadrži (a) vodik, i
The pharmaceutical composition according to claim 2 wherein said pharmaceutically acceptable carrier is comprised of microcrystalline cellulose and mannitol or lactose. 
Farmaceutska smjesa prema zahtjevu 2 gdje se taj farmaceutski prihvatljivi nosač sastoji od mikrokristalične celuoze i manitola ili laktoze.
or a pharmaceutically acceptable salt thereof. The method of claim 1, wherein the compound is 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methyl-benzamide, or a pharmaceutically acceptable salt thereof. 
Spoj formule I, naznačen time, da je to spoj 3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid, ili njegov farmaceutski prihvatljiv derivat određen u zahtjevu 1, te da je za uporabu prema zahtjevu 1.
The method of claim 18, wherein the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:8. 
(v1) CAR je kodiran sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8.
Use of a compound as in claim 8 in which the inflammatory disorder is selected from the group consisting of asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, pain, and arthritis including rhematoid arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis. 
11. Uporaba spoja prema zahtjevu 10, naznačena time što se radi o upalnom poremećaju iz skupine koja obuhvaća astmu, sindrom respiratornog distresa kod odraslih, kroničnu opstruktivneu plućnu bolest, kroničnu plućnu inflamatornu bolest, dijabetes, upalnu bolest crijeva, osteoporozu, psorijazu, odbacivanja transplantanta, 15
To the resultant solution was added ethyl acetate (15 ml) and hexanes (15 ml) and the solution was stirred for 5 min. 
Rezultirajućoj otopini dodani su etil acetat (15 mL) i heksani (15 mL) i otopina je miješana kroz 5 min.
The compound having the following formula: 
Spoj koji ima slijedeću formulu:
W represents oxygen or sulphur; 
W predstavlja kisik ili sumpor;
The calcium carbonate of said carbonate-comprising material may be a precipitated calcium carbonate (PCC), a natural ground calcium carbonate (NGCC), a surface-reacted calcium carbonate (SRCC), or a mixture thereof. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da kalcijev karbonat iz navedenog materijala koji sadrži kalcijev karbonat je nataloženi kalcijev karbonat (PCC), prirodni usitnjeni kalcijev karbonat (NGCC), površinski reaktivan kalcijev karbonat (SRCC), ili njihova mješavina.